TherapeuSonics Co., Ltd

Core technology: Pressure-Modulated Shockwave Histotripsy

• TherapeuSonics’ core proprietary technology is a next-generation, non-invasive tissue fractionation platform that overcomes the limitations of conventional therapeutic ultrasound. It precisely targets and mechanically fractionates biological tissue using highly engineered ultrasound energy. 

• By utilising pressure-modulated shockwaves, the system initiates localised heating to generate primary vapour bubbles, which then induce a powerful and highly controllable cavitation phenomenon. This mechanism mechanically destroys the targeted tissue without causing damage to the surrounding normal tissue. 

Global Intellectual Property (Granted Patents)

TherapeuSonics holds exclusive rights to pressure-modulated shockwave histotripsy, the foundational technology for next-generation therapeutic ultrasound devices. 

• Apparatus and method for precise mechanical tissue ablation using pressure modulated focused ultrasound (KOR 10-2320038)

• Cavitation based tissue removal device using focused ultrasound (KOR 10-2583983)

• Apparatus and method for precise mechanical tissue ablation using pressure modulated focused ultrasound (US 12053198B2)

• Cavitation based tissue removal device using focused ultrasound (US 12251583B2)

SCI Papers on Pressure-Modulated Shockwave Histotripsy 

• Control of the dynamics of a boiling vapour bubble using pressure-modulated high intensity focused ultrasound without the shock scattering effect: A first proof-of-concept study. Ultrasonics Sonochemistry. (Impact Factor 9.3)

• Noninvasive mechanical destruction of liver tissue and tissue decellularisation by pressure-modulated shockwave histotripsy. Frontiers in Immunology. (Impact Factor 8.7)

• A parametric study of bubble dynamics and lesion formation in liver tissue phantom during pressure-modulated shockwave histotripsy. Scientific Reports. (Impact Factor 3.8)